Table 1.
Antiproliferative activity of dehydroabietic acid-based 1,2,3-triazole compounds a.
| Compound | IC50 (μM) | ||||
|---|---|---|---|---|---|
| CNE-2 | HepG2 | BEL-7402 | HeLa | HL-7702 | |
| 3a (R = H) | 33.40 ± 0.33 | >100 | 36.44 ± 070 | 67.88 ± 0.56 | >100 |
| 3b (R = o-F) | 21.44 ± 0.52 | 25.86 ± 0.27 | 18.63 ± 0.82 | 17.76 ± 0.31 | >100 |
| 3c (R = m-F) | 10.92 ± 0.21 | 5.90 ± 0.41 | 16.72 ± 0.06 | 20.05 ± 0.54 | >100 |
| 3d (R = p-F) | 12.20 ± 0.33 | 20.60 ± 0.09 | 14.84 ± 075 | 22.33 ± 0.35 | >100 |
| 3e (R = o-Cl) | 74.88 ± 0.14 | 45.08 ± 0.33 | 25.06 ± 0.32 | 44.28 ± 0.43 | >100 |
| 3f (R = m-Cl) | 59.03 ± 0.28 | 22.27 ± 0.35 | 26.09 ± 0.15 | 53.78 ± 0.32 | >100 |
| 3g (R = p-Cl) | 60.73 ± 066 | >100 | 38.04 ± 0.48 | >100 | >100 |
| 3h (R = o-Br) | 48.30 ± 0.27 | 35.42 ± 0.21 | 27.26 ± 0.36 | 25.90 ± 0.20 | >100 |
| 3i (R = m-Br) | 44.14 ± 0.22 | 40.66 ± 0.62 | 36.88 ± 0.23 | 56.08 ± 0.36 | >100 |
| 3j (R = p-Br) | >100 | 23.40 ± 0.32 | 14.53 ± 0.62 | 43.18 ± 0.22 | >100 |
| 3k (R = o-NO2) | 44.90 ± 0.32 | 6.25 ± 0.37 | 18.62 ± 0.26 | >100 | >100 |
| 3l (R = m-NO2) | 11.45 ± 0.18 | 15.83 ± 0.64 | 15.39 ± 0.51 | 67.37 ± 0.33 | >100 |
| 3m (R = p-NO2) | 19.61 ± 0.38 | >100 | 22.81 ± 0.22 | 22.48 ± 0.35 | >100 |
| 3n (R = m-CH3) | >100 | 60.18 ± 0.39 | 23.61 ± 0.44 | 25.32 ± 0.81 | >100 |
| 3o (R = p-CH3) | >100 | 51.78 ± 0.43 | 41.89 ± 0.72 | 42.51 ± 0.37 | >100 |
| 3p (R = m-OCH3) | 80.98 ± 0.78 | >100 | 25.03 ± 0.22 | 24.66 ± 0.16 | >100 |
| DHAA | 88.64 ± 0.73 | 80.36 ± 0.84 | 46.70 ± 0.55 | 37.40 ± 0.64 | >100 |
| Cisplatin | 8.75 ± 0.24 | 6.42 ± 0.18 | 12.68 ± 0.33 | 1.94 ± 0.20 | 20.76 ± 0.83 |
a IC50 values are expressed as the mean ± SD (standard deviation) from three independent experiments. The results indicate statistically significant differences at p < 0.05.